BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Provectus Biopharmaceuticals, Inc. PVCT
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$336,108
▼ 45.5% vs FY2024
EPS · FY25
$-0.01
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-1615.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 336,108.00
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 1616 cents on every revenue dollar this year.
Per share
USD -0.01
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-1575.3%
Net margin-1615.8%
Return on assets-637.5%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−30.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.42B
Shares outstanding, FY2025
Change, 5 years+5.4%
Change, 10 years—
The share count grew 5% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 697,502.00
total assets, end of FY2025
Total assetsUSD 697,502.00
EquityUSD -6.3M
CashUSD 251,291.00
Gross debtUSD 241,393.00
Net debtUSD -9,898.00
Current ratio0.08×
The company holds more cash than debt.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.0
0.0
0.0
0.0
·
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
·
·
·
·
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.01
−0.01
−0.01
−0.01
−0.01
−0.02
−0.02
−0.02
−0.04
−0.12
−0.13
−0.06
−0.22
−0.11
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
−246.9
−118.1
−64.4
−502.6
−174.4
−187.6
−184.5
−126.6
−82.5
−67.5
Shares out B
0.42
0.42
0.42
0.42
0.42
0.40
0.39
0.38
0.37
0.36
0.20
0.18
0.16
0.12
0.11
0.09
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed